Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer
April 12 2021 - 8:00AM
Business Wire
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage
precision medicine company developing innovative treatments for
genetically defined age-related macular degeneration (AMD) and
linked ocular disorders, today announced the appointment of Samuel
Barone, M.D., as Gemini’s Chief Medical Officer, effective
immediately.
“We are thrilled to welcome Sam to Gemini as Chief Medical
Officer, where he will bring his expertise as a board-certified
ophthalmologist specializing in the treatment of retinal and
macular diseases,” said Jason Meyenburg, Chief Executive Officer of
Gemini Therapeutics. “As we continue to advance our clinical
pipeline, we will benefit tremendously from his two-plus decades of
clinical and development experience, as well as his deep
understanding of the regulatory landscape, and skills as a
vitreoretinal surgeon.”
Dr. Barone joins Gemini Therapeutics after most recently serving
as co-Founder, Manager and Chief Medical Officer of Halodine, LLC,
a company spun out of Veloce BioPharma. Prior, he held the role of
Chief Medical Officer of Veloce BioPharma. Dr. Barone previously
served as Senior Vice President at Adverum Biotechnologies
(formerly Avalanche Biotechnologies). While at Avalanche
Biotechnologies, Dr. Barone served as Chief Medical Officer. Before
joining Avalanche Biotechnologies, Dr. Barone served as a Medical
Officer in the Office of Cellular, Tissue and Gene Therapies at the
U.S. Food and Drug Administration (FDA).
Dr. Barone received his B.S. in biology from Boston College and
his M.D. from the Pennsylvania State University College of
Medicine. After obtaining his medical degree, Dr. Barone served as
a flight surgeon in the United States Air Force serving active duty
at Andrews Air Force Base and at bases in Korea, Afghanistan, and
Iraq for which he received several military honors. Following his
military service, Dr. Barone completed a residency in ophthalmology
at the New York Eye and Ear Infirmary, where he served as Chief
Resident, as well as a medical and surgical retina fellowship at
the University of California, San Diego.
Dr. Barone is succeeding Marc E. Uknis, M.D., F.A.C.S., who will
be pursuing other opportunities. Marc will continue to contribute
to Gemini in an advisory role. “We extend our gratitude to Dr.
Uknis for the pivotal role he played in advancing GEM103 into
clinical development and helping transform Gemini into a publicly
traded precision medicine company with a promising clinical
pipeline,” continued Mr. Meyenburg.
About Gemini Therapeutics
Gemini Therapeutics is a clinical stage precision medicine
company developing novel therapeutic compounds to treat genetically
defined age-related macular degeneration (AMD). Gemini’s lead
candidate, GEM103, is a recombinant form of the human complement
factor H protein (CFH), designed to address both complement
hyperactivity and restore retinal health in patients with AMD.
GEM103 is currently in a Phase 2a trial in dry AMD patients with a
CFH risk variant. The company has generated a rich pipeline
including recombinant proteins, gene therapies, and monoclonal
antibodies.
For more information, visit www.geminitherapeutics.com.
Gemini’s Forward-Looking Statements
Certain statements in this press release and the information
incorporated herein by reference may constitute “forward-looking
statements” for purposes of the federal securities laws. Our
forward-looking statements include, but are not limited to,
statements regarding our or our management team’s expectations,
hopes, beliefs, intentions or strategies regarding the future,
including those relating to the success, cost and timing of our
product development activities and clinical trials, including our
estimates regarding when data will be reported from ongoing
clinical trials and the timing to commence future clinical trials,
the potential attributes and benefits of our product candidates,
including GEM103, our ability to obtain and maintain regulatory
approval for our product candidates, our projected cash runway and
our ability to obtain funding for our operations when needed.
Forward-looking statements include statements relating to our
management team’s expectations, hopes, beliefs, intentions or
strategies regarding the future. In addition, any statements that
refer to projections, forecasts or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking statements. The words
“anticipate,” “believe,” “contemplate,” “continue,” “could,”
“estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions may identify forward-looking
statements, but the absence of these words does not mean that a
statement is not forward-looking. These forward-looking statements
are based on current expectations and beliefs concerning future
developments and their potential effects. There can be no assurance
that future developments affecting us will be those that we have
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond our control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, those factors described under the heading
“Risk Factors” in the final proxy/prospectus for our recently
completed business combination, and those that are included in any
of our future filings with the SEC. Should one or more of these
risks or uncertainties materialize, or should any of our
assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Some of these risks and uncertainties may in the future be
amplified by the COVID-19 pandemic and there may be additional
risks that we consider immaterial, or which are unknown. It is not
possible to predict or identify all such risks. Our forward-looking
statements only speak as of the date they are made, and we do not
undertake any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities
laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210412005219/en/
Investors: Argot Partners Sherri Spear 212-600-1902
gemini@argotpartners.com Media: Argot Partners Joshua
Mansbach 212-600-1902 gemini@argotpartners.com
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024